SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-061519
Filing Date
2023-11-09
Accepted
2023-11-09 07:09:22
Documents
13
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ikna-20231109.htm   iXBRL 8-K 89517
2 EX-99.1 ikna-ex99_1.htm EX-99.1 195894
  Complete submission text file 0000950170-23-061519.txt   424840

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikna-20231109_pre.xml EX-101.PRE 11440
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikna-20231109_lab.xml EX-101.LAB 14084
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikna-20231109.xsd EX-101.SCH 2479
7 EXTRACTED XBRL INSTANCE DOCUMENT ikna-20231109_htm.xml XML 4879
Mailing Address 50 NORTHERN AVE. BOSTON MA 02210
Business Address 50 NORTHERN AVE. BOSTON MA 02210 857-343-8292
Ikena Oncology, Inc. (Filer) CIK: 0001835579 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40287 | Film No.: 231390022
SIC: 2836 Biological Products, (No Diagnostic Substances)